# A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting

> **NCT06488170** · — · ACTIVE_NOT_RECRUITING · sponsor: **Almirall, S.A.** · enrollment: 42 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Tildrakizumab

## Key facts

- **NCT ID:** NCT06488170
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-04
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06488170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06488170, "A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06488170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*